On May 13, 2019, Applied Therapeutics conducted its initial public offering (“IPO”), issuing 4 million shares of common stock with a price of $10.00 per share. On August 17, 2020, Applied Therapeutics disclosed that a partial clinical hold on the company’s ACTION-Kids study evaluating the company’s AT-007 product for the treatment of galactosemia was placed by the U.S. Food and Drug Administration (“FDA”). The FDA cited the need for additional technical information related to ensuring that all of the study’s participants have access to the drug’s benefits. Applied Therapeutics’ stock price fell $3.53 per share, or 12.07%, on this news, closing at $25.71 per share on August 17, 2020.
Applied Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048
info@portnoylaw.com
